Treatment of Inflammatory Bowel Disease with Biologics

(C. Jardin) #1

30


trying a second anti-TNFα agent. We do not advocate switching unless the patient
has lost response or been intolerant to a specific anti-TNFα therapy because this will
increase the risk of the development of antibodies to the previous anti-TNFα ther-
apy. Additionally, it has been shown that those patients started on a second anti-
TNFα therapy generally have a lower response and remission rate compared to the
first anti-TNFα agent. The utilization of concomitant immune suppression with
anti-TNFα therapy will be discussed in detail in another chapter. However, in gen-
eral we recommend that the majority of patients, unless there is intolerance or
contraindication, should be on concomitant immune suppression when on an anti-
TNFα therapy.
Patient education regarding the risks and benefits of anti-TNFα therapy is criti-
cal. It is also extremely important for patients to understand that interruption of
therapy can result in antibody formation and loss of response. Therefore, adher-
ence is an essential issue with regard to the long-term maintenance with anti-
TNFα therapy.
In summary, for UC patients who have failed first-line therapy, anti-TNFα ther-
apy can be utilized for the induction and maintenance of remission. Anti-TNFα
therapy is relatively safe and effective for the treatment of UC provided patients are
selected to ensure there are no treatment contraindications and that all patients are
monitored carefully.


References


  1. Langholz E, Munkholm P, Davidsen M, Binder V.  Colorectal cancer risk and mortality in
    patients with ulcerative colitis. Gastroenterology. 1992;103(5):1444–51.

  2. Solberg IC, Lygren I, Jahnsen J, Aadland E, Hoie O, Cvancarova M, et  al. Clinical course
    during the first 10 years of ulcerative colitis: results from a population-based inception cohort
    (IBSEN Study). Scand J Gastroenterol. 2009;44(4):431–40.

  3. Gisbert JP, Marin AC, McNicholl AG, Chaparro M. Systematic review with meta-analysis: the
    efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous
    anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015;41(7):613–23.

  4. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of
    Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105(3):501–23;
    quiz 24.

  5. Taleban S, Colombel JF, Mohler MJ, Fain MJ. Inflammatory bowel disease and the elderly: a
    review. J Crohns Colitis. 2015;9(6):507–15.

  6. Lichtenstein GR, Rutgeerts P.  Importance of mucosal healing in ulcerative colitis. Inflamm
    Bowel Dis. 2010;16(2):338–46.

  7. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of
    mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7(1):15–29.

  8. Rutter M, Saunders B, Wilkinson K, Rumbles S, Schofield G, Kamm M, et  al. Severity of
    inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology.
    2004;126(2):451–9.

  9. Dave M, Loftus EV Jr. Mucosal healing in inflammatory bowel disease-a true paradigm of
    success? Gastroenterol Hepatol (N Y). 2012;8(1):29–38.

  10. Shah SC, Colombel JF, Sands BE, Narula N.  Mucosal healing is associated with improved
    long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis.
    Clin Gastroenterol Hepatol. 2016;14(9):1245–55.


K. Clark-Snustad et al.
Free download pdf